Study of Nutraceuticals and Phytochemicals for the Management of Alzheimer's Disease: A Review

Ahmad, Syed Sayeed; Khalid, Mohammad; Kamal, Mohammad Amjad; Younis, Kaiser

doi:10.2174/1570159x19666210215122333

Cited by 13 publications

(9 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The multi-target activities of doxycycline in different experimental conditions are shared by several other compounds, mainly of natural origin ( Wu et al, 2019 ; Ahmad et al, 2021 ; Maccioni et al, 2022 ). Rifampicin, another well-known antibiotic that independently of its anti-infectivity action has an important neuroprotective function: anti-AβOs, anti-TauOs and anti-inflammatory activities have been demonstrated by rifampicin in various experimental models ( Umeda et al, 2016 ) with a mechanism similar to that described for doxycycline ( Yulug et al, 2018 ).…”

Section: Oligomers and Inflammationmentioning

confidence: 99%

Oligomeropathies, inflammation and prion protein binding

2022

View full text Add to dashboard Cite

The central role of oligomers, small soluble aggregates of misfolded proteins, in the pathogenesis of neurodegenerative disorders is recognized in numerous experimental conditions and is compatible with clinical evidence. To underline this concept, some years ago we coined the term oligomeropathies to define the common mechanism of action of protein misfolding diseases like Alzheimer, Parkinson or prion diseases. Using simple experimental conditions, with direct application of synthetic β amyloid or α-synuclein oligomers intraventricularly at micromolar concentrations, we could detect differences and similarities in the biological consequences. The two oligomer species affected cognitive behavior, neuronal dysfunction and cerebral inflammatory reactions with distinct mechanisms. In these experimental conditions the proposed mediatory role of cellular prion protein in oligomer activities was not confirmed. Together with oligomers, inflammation at different levels can be important early in neurodegenerative disorders; both β amyloid and α-synuclein oligomers induce inflammation and its control strongly affects neuronal dysfunction. This review summarizes our studies with β-amyloid or α-synuclein oligomers, also considering the potential curative role of doxycycline, a well-known antibiotic with anti-amyloidogenic and anti-inflammatory activities. These actions are analyzed in terms of the therapeutic prospects.

show abstract

Section: Oligomers and Inflammationmentioning

confidence: 99%

Oligomeropathies, inflammation and prion protein binding

2022

View full text Add to dashboard Cite

show abstract

“…Polydatin's various effects suggest that it might be a viable neuroprotective drug in the treatment of AD pathology. [50] Pyrroloquinoline quinone (PQQ)…”

Section: Trans ε-Vaneferinmentioning

confidence: 99%

Exploring the potential of neuronutraceuticals as alternatives in the prevention of Alzheimer’s disease

Kumar¹,

Ali²,

Kumar³

et al. 2022

Pharmaspire

View full text Add to dashboard Cite

Various chemical compounds with natural dietary origins have been shown to protect against age-related disorders, such as neurodegenerative diseases such as Alzheimer’s disease (AD). Such substances are known as nutraceuticals, and they differ structurally, function at distinct biochemical and metabolic levels, and have various neuroprotective characteristics. In this review, we analyzed the evidence from explanatory studies on the effects of selected nutritional supplements on age-related cognitive decline and dementia in humans, randomized clinical trials, and clinical trials. We provide findings from research on vitamins, flavonoids, and other natural compounds that have been researched in AD and may be useful for maintaining excellent cognitive function. In dementia-related therapy, nutraceuticals are not a choice due to a severe absence of high-quality research studies. Despite this, the significant potential for their neuroprotective effects discourages future research.

show abstract

“…Nutraceuticals are ingested in concentrated forms such as tablets, capsules, and drinks, and they have no negative effects, even at large doses. To avoid the negative side effects of the currently available medications, researchers are concentrating their efforts on identifying natural bioactive chemicals found in foods that can be used to treat AD [11][12][13][14]. The consumption of bioactive compound-rich foods or the administration of bioactive compound extracts can have a preventive impact against a variety of pathophysiological diseases.…”

Section: Introductionmentioning

confidence: 99%

Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer’s Disease

Wang¹,

Kong²,

Chen

et al. 2022

Molecules

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurological condition. The rising prevalence of AD necessitates the rapid development of efficient therapy options. Despite substantial study, only a few medications are capable of delaying the disease. Several substances with pharmacological activity, derived from plants, have been shown to have positive benefits for the treatment of AD by targeting various enzymes, such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), β-secretase, γ-secretase, and monoamine oxidases (MAOs), which are discussed as potential targets. Medicinal plants have already contributed a number of lead molecules to medicine development, with many of them currently undergoing clinical trials. A variety of medicinal plants have been shown to diminish the degenerative symptoms associated with AD, either in their raw form or as isolated compounds. The aim of this review was to provide a brief summary of AD and its current therapies, followed by a discussion of the natural compounds examined as therapeutic agents and the processes underlying the positive effects, particularly the management of AD.

show abstract

Study of Nutraceuticals and Phytochemicals for the Management of Alzheimer's Disease: A Review

Cited by 13 publications

References 143 publications

Oligomeropathies, inflammation and prion protein binding

Oligomeropathies, inflammation and prion protein binding

Exploring the potential of neuronutraceuticals as alternatives in the prevention of Alzheimer’s disease

Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer’s Disease

Contact Info

Product

Resources

About